Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 3554

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1A
Chunk 3554
---
 business. Further, future government shutdowns could impact our ability
to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.

We
are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations.
We can face serious consequences for violations.

117

Among
other matters, U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations,
which are collectively referred to as Trade Laws, prohibit companies and their employees, agents, clinical research organizations, legal
counsel, accountants, consultants, contractors, and other partners from authorizing, promising, offering, providing, soliciting, or receiving
directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector.
Violations of Trade Laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment,
tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions
with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We also
expect our non-U.S. activities to increase in time. We plan to engage third parties for clinical trials and/or to obtain necessary permits,
licenses, patent registrations, and other regulatory approvals and we can be held liable for the corrupt or other illegal activities
of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities.

If
we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur
costs that could have a material adverse effect on the success of our business.

Our
research and development activities and our third-party manufacturers’ and suppliers’ activities involve the controlled storage,
use, and disposal of hazardous materials, including the components of our product candidates and other hazardous compounds. We and our
manufacturers and suppliers are subject to laws and regulations governing the use, manufacture, storage, handling, and disposal of these
hazardous materials. In some cases, these hazardous materials and various wastes resulting from their use are stored at our and our manufacturers’
facilities pending their use and disposal. We cannot eliminate the risk of contamination, which could cause an interruption of our commercialization
efforts, research and development efforts, and business operations, and cause